Aligos Therapeutics
ALGS
52 hedge funds and large institutions have $30.4M invested in Aligos Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.23% less ownership
Funds ownership: 3.01% → 2.78% (-0.23%)
12% less funds holding
Funds holding: 59 → 52 (-7)
16% less capital invested
Capital invested by funds: $36M → $30.4M (-$5.66M)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$168K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$155K |
| 3 |
Rockefeller Capital Management
New York
|
+$103K |
| 4 |
NM
Newtyn Management
New York
|
+$50.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.85M |
| 2 |
Renaissance Technologies
New York
|
-$229K |
| 3 |
Millennium Management
New York
|
-$176K |
| 4 |
D.E. Shaw & Co
New York
|
-$164K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$114K |
ALGS Hedge Fund Activity: Q3 2022 in Review
52 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2022, worth a combined $30.4M — down 16% from $36M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ALGS and 5 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 12 added.
The largest buyer was Tang Capital Management, adding an estimated $168K. The largest seller was Boxer Capital, exiting entirely with an estimated $1.85M sold.
- 52 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2022, down from 59 in Q2 2022.
- Funds reported $30.4M of Aligos Therapeutics stock for Q3 2022, down 16% quarter-over-quarter.
- 5 funds opened new Aligos Therapeutics positions in Q3 2022 and 12 closed out, a net change of -7 holders.
- The largest Aligos Therapeutics buyer in Q3 2022 was Tang Capital Management, an estimated $168K added.
- The largest Aligos Therapeutics seller in Q3 2022 was Boxer Capital, an estimated $1.85M sold.
Based on aggregated 13F filings for Q3 2022.